Biohaven Ltd.
BHVN
Jodie situation report
Biohaven Ltd.'s move is being confirmed by its market group.
No new filing conclusion is available. 12 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ATAI begins moving with the group.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind BHVN
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
REGNRegeneron Pharmaceuticals, Inc.partnerNov 10, 2025 ▾
“39 Table of Contents • Antibody Drug Conjugates ◦ BHV-1510 Phase 1/2 study in epithelial tumors: In May 2025, we reported further preliminary data from the study, where BHV-1510 demonstrated encouraging early clinical activity in combination with Regeneron's…”
Depended on by
CLYMClimb Bio, Inc.competitorMay 7, 2026 ▾
“In addition, companies targeting CD38, such as Biogen Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
BHVN is currently a Participant in the organic co-movement group Biotech Cancer Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.